CN106266565A - 一种弓形虫病的药物及该药物的制备方法 - Google Patents
一种弓形虫病的药物及该药物的制备方法 Download PDFInfo
- Publication number
- CN106266565A CN106266565A CN201610796809.9A CN201610796809A CN106266565A CN 106266565 A CN106266565 A CN 106266565A CN 201610796809 A CN201610796809 A CN 201610796809A CN 106266565 A CN106266565 A CN 106266565A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- preparation
- toxoplasmosis
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 70
- 201000005485 Toxoplasmosis Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000000605 extraction Methods 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 238000001694 spray drying Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000012567 medical material Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 241001106462 Ulmus Species 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 210000002421 cell wall Anatomy 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 238000000889 atomisation Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006199 nebulizer Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 241000717739 Boswellia sacra Species 0.000 claims description 2
- 235000011293 Brassica napus Nutrition 0.000 claims description 2
- 240000008100 Brassica rapa Species 0.000 claims description 2
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 claims description 2
- 239000004863 Frankincense Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 241000223996 Toxoplasma Species 0.000 abstract description 47
- 230000000694 effects Effects 0.000 abstract description 18
- 238000009395 breeding Methods 0.000 abstract description 7
- 230000001488 breeding effect Effects 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 6
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 238000002203 pretreatment Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000001629 suppression Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000003812 trophozoite Anatomy 0.000 description 5
- 208000030852 Parasitic disease Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000002045 Ancylostomiasis Diseases 0.000 description 1
- 208000033211 Ankylostomiasis Diseases 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020376 Hookworm infection Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000243653 Tubifex Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229930191701 arteannuin Natural products 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000001843 schistosomicidal effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/264—Aristolochia (Dutchman's pipe)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种治疗弓形虫病的药物及制备方法，包括以下按重量计的配方组成：枸杞子20～30份；乌梅50～60份；商陆30～40份；青蒿10～20份；蒲公英70～80份；黄精20～35份；柴胡10～15份；牡蛎20～30份；白茯苓40～50份；通过原材料预处理，将按上述配方进行混合，混合后浸泡2～5天，搅拌均匀至充分溶解，通过萃取工艺将上述溶解后的溶液进行提取，得到提取药，再通过喷雾干燥加工成萃取粉，即得到治疗弓形虫病的药物；本发明的药物能有效地抑制弓形虫的繁殖，并逐步从人体或动物体内彻底驱除，且该药物无毒无副作用。上述制备方法简单易操作，制备的治疗弓形虫病的药物效果优异，解决了长期以来，弓形虫病不能得到很好的抑制和驱除的问题。
Description
技术领域
本发明涉及弓形虫药物领域，尤其涉及一种治疗弓形虫病的药物及该药物的制备方法。
背景技术
弓形虫为细胞内寄生虫，在人体细胞内以胞囊和滋养体两种形态存在，滋养体在细胞内吞噬养分并迅速繁殖，破坏人体组织器官的正常功能，降低人体自身的固有免疫力。患者在患病初期无明显症状，免疫力低到一定程度待其它病症发作时，弓形虫病又被其他病症所掩盖。
现有技术中，一般是采用西药产品对弓形虫的繁殖和滋养进行抑制，常规治疗弓形虫病的西药一般采用口服螺旋霉素或口服磺胺类药物，这些药物都有较大的副作用，况且也都只能抑制滋养体的繁殖，而不能杀死滋养体。因此，该弓形虫的繁殖对人类及动物造成严重的健康及生命威胁，有必要研发一种药物对弓形虫进行抑制并能彻底驱除。
发明内容
为此，本发明所要解决的技术问题在于，针对上述现有技术的不足，提供一种治疗弓形虫病的药物，该药物无毒无副作用，使用该药物能有效地抑制弓形虫的繁殖，并逐步从人体或动物体内彻底驱除。
本发明要解决的另一个技术问题是提供一种治疗弓形虫病药物的制备方法，该方法简单，易于操作。
为解决上述技术问题，本发明解决该技术问题的技术方案是，提供一种治疗弓形虫病的药物，其中，包括以下按重量计的配方组成：枸杞子20～30份；乌梅50～60份；商陆30～40份；青蒿10～20份；蒲公英70～80份；黄精20～35份；柴胡10～15份；牡蛎20～30份；白茯苓40～50份。
进一步地，本发明的优选方案是：包括以下按重量计的配方组成：枸杞子25份；乌梅55份；商陆35份；青蒿15份；蒲公英75份；黄精30份；柴胡12份；牡蛎15份；白茯苓45份。
进一步地，所述的药物还包括按重量计的以下成份中的一种或两种以上：贯众0.6～0.8份；芜荑0.5～0.8；桑白皮2～6。
本发明的优选方案是：所述的药物还包括按重量计的以下成份中的一种或两种以上：白芦1.0～1.2；蜀漆0.7～1.0；青木香1～3；白槟榔1.0～1.5；狗脊1～3；大黄0.1～0.3；乳香1.0～1.5；白术付0.7～1.0；芜箐子0.8～1.0。
本发明提供的另一技术方案是：提供一种治疗弓形虫药物的制备方法：包括以下步骤：
(1)将乌梅、蒲公英、白茯苓、青蒿和柴胡进行提取，取其提取物；
(2)将枸杞子、商陆、黄精、牡蛎、贯众、芜荑、桑白皮打磨成粉；
(3)按上述的配比将上述步骤(1)和(2)中的药材进行混合，混合后浸泡2～5天，搅拌均匀至充分溶解；
(4)通过萃取工艺将上述溶解后的溶液进行提取，得到提取药，再通过喷雾干燥加工成萃取粉，即得到治疗弓形虫病的药物。
进一步地，本发明的优选方案是：所述的萃取粉按重量比1:7的比例加入45～60度的酒调配，沉淀5～7天后，再加水调至酒精度数为30度即可服用。
进一步地，本发明的优选方案是：所述的萃取粉按1:10的比例加水进行调配，沉淀5～7天后，即可服用。
进一步地，本发明的优选方案是：上述的步骤(2)中，打磨成粉的药材粒径为1～10μm，细胞破壁率为95％。
进一步地，本发明的优选方案是：上述的步骤(4)中，所述的喷雾干燥包括以下步骤：
(1)提取药先进行预处理，均质和预热杀菌；
(2)再将提取药进行真空浓缩，去除提取药中70～80％的水分；
(3)在高压或离心力作用下，浓缩后的提取药通过雾化器向干燥室喷成雾状，使提取药干燥成颗粒，得到萃取粉；
(4)冷却后，贮存。
进一步地，本发明的优选方案是：所述的提取药预热杀菌是指80～85℃的温度下加热5～10分钟或在90～95℃温度下加热10～20秒。
本发明与现有技术相比的有益效果是，通过上述的技术方案的药物，能有效地抑制弓形虫的繁殖，并逐步从人体或动物体内彻底驱除，且该药物无毒无副作用。上述制备方法简单易操作，制备的治疗弓形虫病的药物效果优异，解决了长期以来，弓形虫病不能得到很好的 抑制和驱除的问题。
附图说明
图1是一般成年的患者服用本药物之前弓形虫检测图像；
图2是一般成年的患者服用本药物之后弓形虫检测图像；
图3是65岁患者服用本药物之前弓形虫检测图像；
图4是65岁患者服用本药物之后弓形虫检测图像；
图5是高血压患者服用本药物之前弓形虫检测图像；
图6是高血压患者服用本药物之后弓形虫检测图像；
图7是贫血患者服用本药物之前弓形虫检测图像；
图8是贫血患者服用本药物之后弓形虫检测图像。
具体实施方式
使用以下实施例对本发明进行进一步阐述。
本发明实施例提供一种治疗弓形虫病的药物，其最佳实施方式如下：
按重量份计：
本发明实施例制备上述治疗弓形虫病药物的制备方法，包括以下步骤：
(1)将乌梅、蒲公英、白茯苓、青蒿和柴胡进行提取，取其提取物；
(2)将枸杞子、商陆、黄精、牡蛎打磨成粉，使药材粒径为1～10μm，细胞破壁率为95％。
(3)按上述的配比将上述步骤(1)和(2)中的药材进行混合，混合后浸泡2～5天，搅拌均匀至充分溶解；
(4)通过萃取工艺将上述溶解后的溶液进行提取，得到提取药，再通过喷雾干燥加工成萃取粉，即得到治疗弓形虫病的药物。
上述打磨成粉是通过超微粉碎技术进行打磨，是利用超声粉碎、超低温粉碎技术，使药材中心粒径在5～10μm以下，细胞破壁率达到95％，从而药效成分易于提取也容易被人体直接吸收，不仅适合于各种不同质地的药材，而且还可使其中的有效成分直接暴露出来，从而使药材成分的溶出和起效更加迅速完全。
上述的步骤中，所述的喷雾干燥包括以下步骤：
(1)提取药先进行预处理，均质和预热杀菌；
(2)再将提取药进行真空浓缩，去除提取药中70～80％的水分；
(3)在高压或离心力作用下，浓缩后的提取药通过雾化器向干燥室喷成雾状，使提取药干燥成颗粒，得到萃取粉；
(4)冷却后，贮存。刚出料的粉剂温度达60℃左右，应冷却到常温下进行包装、贮存。
上述的提取药预热杀菌是指80～85℃的温度下加热5～10分钟或在90～95℃温度下加热 10～20秒，预热杀菌的目的在于杀死液体中的细菌。
上述喷雾干燥得到的萃取粉按重量比1:7的比例加入45～60度的酒调配，沉淀5～7天后，再加水调至酒精度数为30度即可服用；或上述的萃取粉按1:10的比例加水进行调配，沉淀5～7天后，即可服用。
通过上述方法将配方1-8让患者服用，其效果如下:(结合图再扫描一下前后的效果)
如图1所示，其为一般成年的患者服用本药物之前通过弓形虫检测仪进行检测得到的图像，可以看出，弓形虫密集，活动力强，通过将配方1-2调配好后让患者服用三个月，其检测图如图2所示，明显可以看出，弓形虫明显减少，且活动量小了许多。
如图3所示，其为65岁患者检测得到的图像，可以看出，其弓形虫的数量明显多于普通成年患者，而且弓形虫活动更加频繁，让其服用配方3-4三个月后，图检测图如图4所示，明显可以看出，弓形虫明显减少，且活动量小了许多。
如图5所示，其为高血压患者检测得到的图像，可以看出，其弓形虫的数量明显多于普通患者，而且弓形虫活动更加频繁，让其服用配方5-6三个月后，图检测图如图6所示，明显可以看出，弓形虫明显减少，且活动量小了许多。
如图7所示，其为贫血患者检测得到的图像，可以看出，其弓形虫的数量明显多于普通患者，而且弓形虫活动更加频繁，让其服用配方7-8三个月后，图检测图如图8所示，明显可以看出，弓形虫明显减少，且活动量小了许多。
从上述实施例可以看出，服用本发明所述的药品，可以抑制弓形虫囊体和滋养体的繁殖，继续服用能彻底驱除弓形虫。
本发明使用的药材的主要功效如下：
【青蒿】主要功效
1、抗血吸虫：杀灭作用；花枝睾吸虫。
2、促免疫作用：可提高淋巴细胞的转化率，促进机体细胞的免疫作用。
3、抗病原微生物作用：青蒿水煎剂对多种细菌有抑制作用。挥发油对皮肤癣有杀灭作用。4、对心血管系统：青蒿素能减慢心率、抑制心肌收缩力、降低冠脉流量药用价值；清透虚热，凉血除蒸，解暑，截疟。用于暑邪发热，阴虚发热，夜热早凉，骨蒸劳热，疟疾寒热，湿热黄疸。实验证明；青蒿提取物对弓形虫有极强的抑制作用。
【乌梅】主要功效
收敛生津，安蛔驱虫。治久咳，虚热烦渴，久疟，久泻，痢疾，便血，尿血，血崩，蛔厥腹痛、呕吐，钩虫病，牛皮癣，胬肉。实验证明；长期对弓形虫携带者服用乌梅，弓形虫 明显减少可以起到有效清除作用。
【蒲公英】主要功效
清热解毒、消炎泻火、等功效。
【白茯苓】主要功效
宁心安神、健脾和胃、失眠健忘、等功效实验证明：乌梅、蒲公英、白茯苓、青蒿、提取物，经过萃取工艺制成粉剂，调配后形成新的药理作用，实验于弓形虫活体，结果显示2个时辰以后弓形虫由活动状态变成静止状态有效控制了弓形虫的滋生，使弓形虫排除体外，服用一个月以后，显微镜显示弓形虫明显减少对弓形虫有强力清除作用
【柴胡】主要功效
促进免疫功能柴胡能使吞噬功能增强、自然杀伤细胞功能增强。提高病毒特异性抗体滴度。提高淋巴细胞转核率，实验结果，加柴胡提取液可以增强产品功效。
【商陆】主要功效
1、治疗血小板减少性紫癜；
2、治疗肾炎及血吸虫肝硬化引起的腹水症实验证明：商陆提取液不仅可以治疗吸血虫肝硬化，对弓形虫也起到抑制作用，主料里加入商陆粉剂一起服用形成新的药理反应，可以增强产品功效
【牡蛎】主要功效
1、牡蛎是一种高蛋白、低脂肪、容易消化且营养丰富的食品，含有丰富的甘氨酸和一种名为肝糖原的糖类物质，它们的牡蛎美味的基础。
2.干牡蛎肉含蛋白质高达45％～57％、脂肪7％～11％、肝糖原19％～38％。此外，还含有多种维生素及牛磺酸和钙、磷、铁、锌等营养成分。其中钙含量接近牛奶，铁含量为牛奶的21倍。实验证明：加入牡蛎粉可以增强弓形虫病患者的恢复能力。
【枸杞子】主要功效
补血安神，生津止渴，润肺止咳。治肝肾阴亏，腰膝酸软，头晕，目眩，目昏多泪，虚劳咳嗽，消渴，遗精。现代药理学研究证实枸杞子可调节机体免疫功能、能有效抑制肿瘤生长和细胞突变实验证明：加入枸杞粉可以增强弓形虫病患者的恢复能力。
【贯众】主要功效
杀虫；清热；解毒；凉血止血
主治用于风热感冒；温热癍疹；吐血；咳血；衄血；便血；崩漏；血痢；带下及钩、蛔、绦虫等肠寄生虫病。
弓形虫检测仪实验证明：对弓形虫有同样的抑制祛除的作用
【芜荑】主要功效
杀虫；清热；解毒；凉血止血
主治用于风热感冒；温热癍疹；吐血；咳血；衄血；便血；崩漏；血痢；带下及钩、蛔、绦虫等肠寄生虫病。
弓形虫检测仪实验证明：对弓形虫有同样的抑制祛除
【桑白皮】
1.降压作用桑白皮的醇提取液5～6mg/kg，对麻醉兔、犬十二指肠给药可使动物血压明显而持久的下降。而对实验性肾性高血压的动物20g/kg口服，亦能产生明显的降压作用
2.利尿作用
3.镇静镇痛作用
4.抗炎作用桑白皮水提取物给大鼠口服或注射对角叉菜胶及葡聚糖所引起的脚肿胀有抑制作用
5.抗菌作用桑白皮煎剂对金黄色葡萄球菌对伤寒杆菌及福氏痢疾杆菌有抑制作用
6降糖作用桑白皮中分离并证实了降血糖成分Moranoline(脱二氧亚胺基葡萄醇)和MoranA降糖物质，经过试验，已经证实了，MoranA对四氧嘧啶诱发的高血糖小鼠(血糖250～450mg/dL)有剂量依赖的降糖效果
桑白皮与祛除弓形虫植物芜荑、狗脊，结合使用能提高药效。
上述药材混合后，在相互药理作用下，会起到非常好的抑制弓形虫并最终驱除作用。
显然，上述实施例仅仅是为清楚地说明所作的举例，而并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (10)
1.一种治疗弓形虫病的药物，其特征在于，包括以下按重量计的配方组成：
2.根据权利要求1所述的药物，其特征在于，包括以下按重量计的配方组成：
3.根据权利要求1或2所述的药物，其特征在于，所述的药物还包括按重量计的以下成份中的一种或两种以上：贯众0.6～0.8份；芜荑0.5～0.8；桑白皮2～6。
4.根据权利要求1或2所述的药物，其特征在于，所述的药物还包括按重量计的以下成份中的一种或两种以上：白芦1.0～1.2；蜀漆0.7～1.0；青木香1～3；白槟榔1.0～1.5；狗脊1～3；大黄0.1～0.3；乳香1.0～1.5；白术付0.7～1.0；芜箐子0.8～1.0。
5.一种治疗弓形虫病药物的制备方法，其特征在于，包括以下步骤：
(1)将乌梅、蒲公英、白茯苓、青蒿和柴胡进行提取，取其提取物；
(2)将枸杞子、商陆、黄精、牡蛎、贯众、芜荑、桑白皮打磨成粉；
(3)按权利要求3配比将上述步骤(1)和(2)中的药材进行混合，混合后浸泡2～5天，搅拌均匀至充分溶解；
(4)通过萃取工艺将上述溶解后的溶液进行提取，得到提取药，再通过喷雾干燥加工成萃取粉，即得到治疗弓形虫病的药物。
6.根据权利要求5所述的制备方法，其特征在于，所述的萃取粉按重量比1:7的比例加入45～60度的酒调配，沉淀5～7天后，再加水调至酒精度数为30度即可服用。
7.根据权利要求5所述的制备方法，其特征在于，所述的萃取粉按1:10的比例加水进行调配，沉淀5～7天后，即可服用。
8.根据权利要求5所述的制备方法，其特征在于，所述的步骤(2)中，打磨成粉的药材粒径为1～10μm，细胞破壁率为95％。
9.根据权利要求5所述的制备方法，其特征在于，所述的步骤(4)中，所述的喷雾干燥包括以下步骤：
(1)提取药先进行预处理，均质和预热杀菌；
(2)再将提取药进行真空浓缩，去除提取药中70～80％的水分；
(3)在高压或离心力作用下，浓缩后的提取药通过雾化器向干燥室喷成雾状，使提取药干燥成颗粒，得到萃取粉；
(4)冷却后，贮存。
10.根据权利要求9所述的制备方法，其特征在于：所述的提取药预热杀菌是指80～85℃的温度下加热5～10分钟或在90～95℃温度下加热10～20秒。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610796809.9A CN106266565A (zh) | 2016-08-31 | 2016-08-31 | 一种弓形虫病的药物及该药物的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610796809.9A CN106266565A (zh) | 2016-08-31 | 2016-08-31 | 一种弓形虫病的药物及该药物的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106266565A true CN106266565A (zh) | 2017-01-04 |
Family
ID=57710295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610796809.9A Pending CN106266565A (zh) | 2016-08-31 | 2016-08-31 | 一种弓形虫病的药物及该药物的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106266565A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107280004A (zh) * | 2017-05-17 | 2017-10-24 | 四川大彭氏国生物科技有限公司 | 一种强制干预驱逐弓形虫的药膳组合物及其制备方法 |
| CN110051808A (zh) * | 2019-05-15 | 2019-07-26 | 陈云志 | 用于治疗弓形虫病的中药组合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1235035A (zh) * | 1998-05-13 | 1999-11-17 | 孙宝江 | 一种治疗弓形虫病的药品及配方 |
| CN1249948A (zh) * | 1999-09-15 | 2000-04-12 | 李永光 | 常青抗弓形虫散 |
| CN1969913A (zh) * | 2006-11-29 | 2007-05-30 | 程跃辉 | 一种治疗弓形虫病的药物 |
-
2016
- 2016-08-31 CN CN201610796809.9A patent/CN106266565A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1235035A (zh) * | 1998-05-13 | 1999-11-17 | 孙宝江 | 一种治疗弓形虫病的药品及配方 |
| CN1249948A (zh) * | 1999-09-15 | 2000-04-12 | 李永光 | 常青抗弓形虫散 |
| CN1969913A (zh) * | 2006-11-29 | 2007-05-30 | 程跃辉 | 一种治疗弓形虫病的药物 |
Non-Patent Citations (2)
| Title |
|---|
| 国家食品药品监督管理局: ""国家食品药品监督管理局发布第6期药品不良反应信息通报"", 《药物警戒》 * |
| 国家食品药品监督管理总局: ""关于加强广防己等6种药材及其制剂监督管理的通知 国食药监注[2004]379号"", 《国食药监注[2004]379号》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107280004A (zh) * | 2017-05-17 | 2017-10-24 | 四川大彭氏国生物科技有限公司 | 一种强制干预驱逐弓形虫的药膳组合物及其制备方法 |
| CN110051808A (zh) * | 2019-05-15 | 2019-07-26 | 陈云志 | 用于治疗弓形虫病的中药组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103141710B (zh) | 一种断奶仔猪配合饲料及其制备方法 | |
| CN104068284B (zh) | 用于治疗小鹅瘟的配合饲料及其制备方法 | |
| CN103689296B (zh) | 妊娠后期和哺乳期的母羊饲料及其制备方法 | |
| CN102178100B (zh) | 一种低色氨酸杂交鸡饲料及其制备方法 | |
| CN103652361A (zh) | 一种产后1-20天哺乳期母猪饲料及其制备方法 | |
| CN103156095A (zh) | 一种肉雏鸡配合饲料及其制备方法 | |
| CN105597071A (zh) | 用于治疗仔猪缺铁性贫血的中药组合物及其制备方法 | |
| CN103285145A (zh) | 一种促进猪快速生长的纯中药制剂及制备方法和使用方法 | |
| CN107998313A (zh) | 一种治疗痛风病的中药酵素及其制备方法 | |
| CN104256166A (zh) | 一种用于治疗牛蓝舌病的功能性饲料及其制备方法 | |
| CN104258139A (zh) | 一种用于防治慢性型猪瘟疫的药物组合物及其制备方法 | |
| CN104256165A (zh) | 用于防治慢性型猪瘟疫的功能性饲料及其制备方法 | |
| CN102697842A (zh) | 多奶灵合剂及制备工艺 | |
| CN103212031B (zh) | 用于治疗原发性肾病综合征的中药组合物及其制备方法 | |
| CN106266565A (zh) | 一种弓形虫病的药物及该药物的制备方法 | |
| CN102327340B (zh) | 家禽用中药颗粒剂及其制备方法 | |
| CN105028995A (zh) | 一种配合狗粮及其制备方法 | |
| CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
| CN106306466A (zh) | 一种治疗猪肺疫的饲料及其制作方法 | |
| CN104970223A (zh) | 一种牛配合饲料及其制备方法 | |
| CN103566312B (zh) | 一种治疗猪食欲不振的中药组合物 | |
| CN103652490A (zh) | 用于治疗猪蓝耳病的猪饲料及其制备方法 | |
| CN1305491C (zh) | 一种治疗肠易激综合征的中药组合物及其制备方法 | |
| CN106309879A (zh) | 一种抗动物应激的药物组合物及其制备方法 | |
| CN106109908A (zh) | 一种治疗羊焦虫病的蒙药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |